VectivBio

VectivBio is a biotech company founded in 2019 based in Switzerland. The company's mission is to develop treatments for severe rare diseases and aims to become a global leader with a patient-centric approach. They have received a significant $125.00M investment in post-IPO equity funding from a consortium of investors including Forbion, OrbiMed, Vivo Capital, Marshall Wace, Driehaus Capital Management, TCG Crossover, Venrock Healthcare Capital Partners, Eventide Asset Management, Surveyor Capital, and Frazier Life Sciences on 13 October 2022. The company is dedicated to discovering and developing novel therapies for severe rare ailments with significant unaddressed medical needs. Their goal is to establish a preeminent, wholly integrated global enterprise specializing in severe rare illnesses through a patient-oriented strategy. VectivBio possesses a top-quality squad with extensive proficiency in severe rare ailments and a history of accomplishing research and development, product commercialization, and business expansion for innovative therapies directed towards orphan conditions with significant medical needs. With their strong investor backing and focused approach, VectivBio is poised to make significant strides in addressing unmet medical needs in the biotechnology and healthcare industries.